Labcorp to Release Q2 2024 Financial Results

Labcorp (NYSE: LH) has announced that it will release its financial results for the second quarter of 2024 before the market opens on Thursday, August 1, 2024. The company's more than 67,000 employees serve clients in approximately 100 countries, provided support for 84% of the new drugs and therapeutic products approved in 2023 by the FDA, and performed more than 600 million tests for patients around the world. In the second quarter of 2024, Labcorp's financial performance is expected to be a focal point for investors and analysts.

During the last reported period, Labcorp reported a revenue of $3.94 billion, a net income of $337.5 million, and an earnings per share of $3.49. Additionally, the company had operating cash flow of $626.1 million and free cash flow of $395.1 million. These figures represented an increase of 38.1% in revenue, 26.7% in net income, and 31.7% in earnings per share compared to the same period in the previous year.

Furthermore, Labcorp's operating cash flow and free cash flow increased by 20.5% and 43.2%, respectively, compared to the previous year. The company's performance in the second quarter of 2024 will be closely scrutinized to assess whether it can maintain its growth trajectory and profitability.

Labcorp's conference call and webcast to discuss the second quarter financial results will commence at 9 a.m. ET on August 1, 2024. The call will be webcast live on the Labcorp Investor Relations website, and a replay of the webcast will be available approximately two hours after the conclusion of the live event and will be accessible until July 18, 2025.

Investors and industry analysts will be keen to examine the upcoming financial results to gauge Labcorp's performance and trajectory in the rapidly evolving global laboratory services market. Today the company's shares have moved -0.2% to a price of $203.13. If you want to know more, read the company's complete 8-K report here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.